PFKFB4 modulated by miR-195-5p can boost the malignant progression of cervical cancer cells

https://doi.org/10.1016/j.bmcl.2022.128916Get rights and content

Abstract

PFKFB4 is dysregulated in varying tumors and has the biological function of regulating tumor progression. However, its biological function in cervical cancer is poorly understood. We obtained the upstream regulatory gene (miR-195-5p) of PFKFB4 through bioinformatics analysis. Then, experiments were introduced to measure expression and targeting relationship of miR-195-5p and PFKFB4 in cervical cancer cells, in order to evaluate their influence on proliferation, migration, invasion and angiogenesis of cervical cancer cells. As expressed in results, PFKFB4 was abnormally increased and boosted malignant progression of cervical cancer cells. Besides, miR-195-5p was markedly decreased and restrained PFKFB4 in cervical cancer. While tumor-suppressive effect of miR-195-5p was partially restored by overexpressing PFKFB4, indicating that miR-195-5p and PFKFB4 may be new therapeutic targets for cervical cancer patients.

Section snippets

Ethics approval and consent to participate

Not applicable.

Consent for publication

All authors consent to submit the manuscript for publication.

Availability of date and materials

The date and materials in the current study are available from the corresponding author on reasonable request.

Funding

This study was supported by the funds from Expression and potential clinical value of ILK in uterine borderline leiomyoma (1901ky85). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Authors’ contributions

All authors contributed to data analysis, drafting and revising the article, gave final approval of the version to be published, and agreed to be accountable for all aspects of the work.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgments

Not applicable.

References (43)

  • Y.H. Chen et al.

    Metformin induces apoptosis and inhibits migration by activating the AMPK/p53 axis and suppressing PI3K/AKT signaling in human cervical cancer cells

    Mol Med Rep

    (2021)
  • M.C. Hsin et al.

    Carbonic anhydrase IX promotes human cervical cancer cell motility by regulating PFKFB4 expression

    Cancers (Basel)

    (2021)
  • J. Meng et al.

    PFKFB4 promotes lung adenocarcinoma progression via phosphorylating and activating transcriptional coactivator SRC-2

    BMC Pulm Med.

    (2021)
  • R. Duan et al.

    Isorhamnetin induces melanoma cell apoptosis via the PI3K/Akt and NF-kappaB pathways

    Biomed Res Int

    (2020)
  • Z. Li et al.

    LINC00941 promoted in vitro progression and glycolysis of laryngocarcinoma by upregulating PKM via activating the PI3K/AKT/mTOR signaling pathway

    J Clin Lab Anal

    (2022)
  • J. Wang et al.

    MicroRNA and mRNA interaction network regulates the malignant transformation of human bronchial epithelial cells induced by cigarette smoke

    Front Oncol

    (2019)
  • V. Vantaku et al.

    Correction: Epigenetic loss of AOX1 expression via EZH2 leads to metabolic deregulations and promotes bladder cancer progression

    Oncogene

    (2020)
  • H. Lu et al.

    Down-regulating NEAT1 inhibited the viability and vasculogenic mimicry formation of sinonasal squamous cell carcinoma cells via miR-195-5p/VEGFA axis

    Biosci Rep

    (2020)
  • B. Yang et al.

    Circular RNA circ_001422 promotes the progression and metastasis of osteosarcoma via the miR-195-5p/FGF2/PI3K/Akt axis

    J Exp Clin Cancer Res

    (2021)
  • W. Li et al.

    CD44 regulates prostate cancer proliferation, invasion and migration via PDK1 and PFKFB4

    Oncotarget

    (2017)
  • H. Lu et al.

    PFKFB4 negatively regulated the expression of histone acetyltransferase GCN5 to mediate the tumorigenesis of thyroid cancer

    Dev Growth Differ

    (2020)
  • View full text